BIRMINGHAM, Ala., Oct. 19, 2022 /PRNewswire/ — Encompass Health Corporation (NYSE: EHC) today announced that its board of directors has declared a quarterly cash dividend on its common stock of $0.15 per share, payable on January 17, 2023, to holders of record on January 3, 2023.
About Encompass Health
Encompass Health (NYSE: EHC) is the largest owner and operator of rehabilitation hospitals in the United States. With a national footprint that includes 153 hospitals in 36 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery. Encompass Health is ranked as one of Fortune’s 100 Best Companies to Work For and Modern Healthcare’s Best Places to Work in Healthcare. For more information, visit encompasshealth.com, or follow us on our newsroom, Twitter, Instagram and Facebook.
Statements contained in this press release which are not historical facts, such as the timing and amounts of dividends, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, Encompass Health, through its senior management, may from time to time make forward-looking public statements concerning the matters described herein. All such estimates, projections, and forward-looking information speak only as of the date hereof, and Encompass Health undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events, or otherwise. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties. Actual events or results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by Encompass Health include, but are not limited to, the regulatory review and approval process; a hospital’s ability to receive and maintain proper local, state and federal licensing; the ability to attract and retain nurses, therapists, and other healthcare professionals in a highly competitive environment with often severe staffing shortages; the continued spread of COVID-19 or another infectious disease, including the speed, depth, geographic reach and duration of the spread, which could decrease our patient volumes and revenues and lead to staffing and supply shortages and associated cost increases; actions to be taken by Encompass Health in response to the pandemic; the legal, regulatory and administrative developments that occur at the federal, state and local levels; Encompass Health’s infectious disease prevention and control efforts; Encompass Health’s ability to comply with extensive, complex, and ever-changing regulations in the healthcare industry; any adverse outcome of various lawsuits, claims, and legal or regulatory proceedings involving Encompass Health, including any matters related to yet undiscovered issues, if any, at acquired companies; potential disruptions, breaches, or other incidents affecting the proper operation, availability, or security of Encompass Health’s information systems, including unauthorized access to or theft of patient, business associate, or other sensitive information; changes, delays in (including in connection with resolution of Medicare payment reviews or appeals), or suspension of reimbursement for Encompass Health’s services by governmental or private payors; and other factors which may be identified from time to time in Encompass Health’s SEC filings and other public announcements, including Encompass Health’s Form 10-K for the year ended Dec. 31, 2021 and Form 10-Q for the quarters ended March 31, 2022, and June 30, 2022.
Casey Winger | 205 447-6410
Investor Relations Contact:
Mark Miller | 205 970-5860
SOURCE Encompass Health Corp.